Santaris Pharma A/S and miRagen Therapeutics Inc. expand worldwide strategic alliance to discover and develop LNA-drugs against

 Santaris Pharma A/S and miRagen Therapeutics Inc. expand worldwide strategic
 alliance to discover and develop LNA-drugs against disease causing microRNAs

  PR Newswire

  HØRSHOLM, Denmark and BOULDER, Colorado, Jan. 8, 2013

HØRSHOLM, Denmark and BOULDER, Colorado, Jan. 8, 2013 /PRNewswire/ -- Santaris
Pharma A/S and miRagen Therapeutics, Inc. today announced that they have
expanded their existing partnership in the field of microRNA therapeutics.

(Logo: http://photos.prnewswire.com/prnh/20100111/SPLOGO )

Under the expanded agreement, miRagen obtains a broad non-exclusive license in
the miRNA therapeutics field for therapeutics research and world-wide
exclusive rights to research, develop and commercialize LNA drugs against up
to six additional microRNA targets that have been shown to be important in
human disease areas of high unmet need. This brings the total number of
microRNA targets under the agreement to ten. Santaris Pharma A/S will receive
a combination of cash and equity in consideration for the licenses as well as
clinical milestones and royalties on products emerging from the alliance.
Financial terms were not disclosed.

Henrik Øerum, CSO and VP, Business Development at Santaris Pharma A/S stated:
"Our collaboration with miRagen is an important part of our corporate strategy
in the microRNA therapeutics field, so we are very pleased with our collective
decision to expand the relationship. MicroRNA therapy is an exciting new
branch of human medicine where the LNA drug platform has already provided
proof-of-concept in phase2 clinical studies in HCV patient using
Santaris´miRNA-122 inhibitor, Miravirsen."

William S. Marshall, President and CEO of miRagen stated: "Our partnership
with Santaris has been very productive, and we are excited to expand the
relationship to additional microRNA targets in our portfolio. Our goal is to
identify important disease causing microRNAs and to deploy the world's best
technologies to create therapeutic development candidates against diseases
with high unmet medical need. We hope these new programs will translate into
novel drugs that will help patients suffering from serious diseases live
longer and better lives."

About Locked Nucleic Acid (LNA) Drug Platform The LNA Drug Platform and Drug
Discovery Engine developed by Santaris Pharma A/S combines the company's
proprietary LNA chemistry with its highly specialized and targeted drug
development capabilities to rapidly deliver LNA-based drug candidates against
RNA targets, both mRNA and microRNA, for a range of diseases including
infectious and inflammatory diseases, cardiometabolic disorders, cancer and
rare genetic disorders. LNA-based drugs are a promising new class of
therapeutics that are enabling scientists to develop drug candidates that
target previously inaccessible clinical pathways. The LNA Drug Platform
overcomes the limitations of earlier antisense and siRNA technologies to
deliver potent single-stranded LNA-based drug candidates across a multitude of
disease states. The unique combination of small size and very high affinity
allows this new class of drug candidates to potently and specifically inhibit
RNA targets in many different tissues without the need for complex delivery
vehicles. The most important features of LNA-based drugs include excellent
specificity providing optimal targeting; increased affinity to targets
providing improved potency; and favorable pharmacokinetic and
tissue-penetrating properties that allow systemic delivery of these drugs
without complex and potentially troublesome delivery vehicles.

About Santaris Pharma A/S Santaris Pharma A/S is a privatel held
clinical-stage biopharmaceutical company focused on the discovery and
development of RNA-targeted therapies. The LNA Drug Platform and Drug
Discovery Engine developed by Santaris Pharma A/S combine the company's
proprietary LNA chemistry with its highly specialized and targeted drug
development capabilities to rapidly deliver potent single-stranded LNA-based
drug candidates across a multitude of disease states. The company's research
and development activities focus on infectious diseases and cardiometabolic
disorders, while partnerships with major pharmaceutical companies include a
range of therapeutic areas including cancer, cardiovascular disease,
infectious and inflammatory diseases, and rare genetic disorders. The company
has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer,
GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent
estate, the company holds exclusive worldwide rights to manufacture, have
manufactured and sell products that contain LNA as an active ingredient for
studies performed with a view to obtaining marketing approval. Santaris Pharma
A/S, founded in 2003, is headquartered in Denmark with operations in the
United States. Please visit www.santaris.com for more information.

About miRagen Therapeutics, Inc. miRagen Therapeutics, Inc. is a
biopharmaceutical company focused on the discovery and development of
innovative microRNA-based therapeutics in disease areas with high unmet
medical need. The company leverages insights from leading laboratories to
evaluate and advance high-potential therapies for its own pipeline or in
conjunction with strategic partners. For several cardiovascular disease
programs, miRagen has partnered with Les Laboratoires Servier, a leading
European pharmaceutical company in the area of cardiovascular disease. miRagen
retains all rights for the Servier-partnered programs in the United States and
Japan. With its commercial and academic alliances, miRagen strives to
harnesses the power of microRNA biology and chemistry by translating
discoveries into breakthrough therapies that improve human health. For more
information, please visit www.miragenrx.com .

Website: http://www.santaris.com
Contact: Santaris, Henrik Øerum, CSO, +45 2834 6474, hoe@santaris.com,
www.santaris.com, or miRagen, Kecia Carroll, Communications, +1-720-933-0848,
Kecia@kcroberg.com
 
Press spacebar to pause and continue. Press esc to stop.